ulipristal acetátu - search results

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

austell anastrazole 1 mg tablet

austell pharmaceuticals (pty) ltd - tablet - see ingredients - each tablet contains : anastrozole 1,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

ella tablet

actor pharma (pty) ltd - applicant - tablet - 30,0 mg - each tablet contains uliphistal acetate 30,0 mg

Ireland - English - HPRA (Health Products Regulatory Authority)

pepcid duo chewable tablets famotidine 10mg magnesium hydroxide 165mg calcium carbonate 800mg

jntl consumer health i (ireland) limited - famotidine; magnesium hydroxide; calcium carbonate - chewable tablet - h2-receptor antagonists; famotidine, combinations

Australia - English - Department of Health (Therapeutic Goods Administration)

itracap itraconazole 100 mg capsule blister pack

arrotex pharmaceuticals pty ltd - itraconazole, quantity: 100 mg - capsule - excipient ingredients: hypromellose; macrogol 20000; sucrose; hydrolysed maize starch; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - itracap is indicated for use in adults for the treatment of: ? superficial dermatomycoses not responding to topical treatment. ? fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening. ? pityriasis versicolor not responding to any other treatment. ? vulvovaginal candidiasis not responding to topical treatment. ? oral candidiasis in immunocompromised patients. ? onychomycosis caused by dermatophytes. ? systemic mycoses: - systemic aspergillosis, histoplasmosis, sporotrichosis. - treatment and maintenance therapy in aids patients with disseminated or chronic pulmonary histoplasmosis infection. - treatment of oropharyngeal and/or oesophageal candidiasis when first line systemic antifungal therapy is inappropriate or has proven ineffective. - treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. this may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.